搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 7 天
时间不限
过去 1 小时
过去 24 小时
过去 30 天
按时间排序
按相关度排序
2 小时
on MSN
Regeneron Pharmaceuticals, Inc. (REGN): Among the Best Genomics Stocks to Buy Right Now
We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we are going to take a look at ...
11 小时
on MSN
Here’s Why Regeneron Pharmaceuticals (REGN) Declined in Q3
Bronte Capital, an investment management company, released its “Amalthea Fund” third-quarter 2024 investor letter. A copy of ...
1 天
Adverum: Ixo-Vec Could Reduce Treatment Burden For Wet-AMD Patients
Adverum Biotechnologies advances wet AMD treatment with promising trial results. See why ADVM stock has potential as it ...
4 天
4D Molecular Therapeutics, Inc.: 4DMT Reports Third Quarter 2024 Financial Results ...
Presented positive interim data for 4D-150 in wet age-related macular degeneration (wet AMD) from PRISM Phase 1/2 clinical trial highlighting robust and durable clinical activity across diverse patien ...
5 天
Eye on the prize: $15.9m boost for Opthea’s vision impairment therapy
Opthea (ASX:OPT) has announced a boost to its cash reserves, receiving a $15.9m research and development tax incentive from ...
5 天
InMed Pharmaceuticals: InMed Reports First Quarter Fiscal 2025 Financial Results and ...
InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary ...
5 天
Ocular Therapeutix™ Reports Third Quarter 2024 Results and Business Highlights
SOL-1 expected to be fully randomized by YE 2024 with topline data expected in Q4 2025 Active clinical trial sites now ...
6 天
4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected ...
Presented positive interim data for 4D-150 in wet age-related macular degeneration (wet AMD) from PRISM Phase 1/2 clinical trial highlighting ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈